olanzapine
Trade name: zyprexa
Approved
Sep 30, 1996
Olanzapine is a novel antipsychotic agent marketed by Lilly & Co. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old. Olanzapine is sometimes used together with other antipsychotic medications or antidepressants. The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with bipolar I disorder is unknown. Olanzapine treatment led to rapid phosphorylation of kinases from all three pathways in PC12 cells. Phosphorylation of Akt was blocked with selective inhibitors (wortmannin and LY294002), which implicates phosphoinositide 3-kinase (PI3K) in the signaling cascade. Short-term mitogenic effects of olanzapine were abolished with a selective inhibitor of Akt, but not by inhibition of the ERK pathway. Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by 2D6. By these mechanisms more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect. Drugs or agents that increase the activity of CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of Olanzapine; conversely, drugs which inhibit 1A2 activity (examples: Ciprofloxacin, Fluvoxamine) may reduce Olanzapine clearance. The most common side effects appear to be somnolence and weight gain. About 11% of patients gain weight -especially if on a high starting dose and if they were underweight pre-treatment. Sexual dysfunction is a problem for many patients, although sexual dysfunction in schizophrneia does not appear to be primarily attributable to drugs. — NCATS
Clinical trial activity
399 trials · 272 clinical orgs · 43 marketing orgs
Earliest trial started Sep 1, 1992 (NCT00000373)
Timeline
1990s
- Sep 30, 1996
Eli Lilly — Earliest FDA Approval
- Sep 30, 1996
Eli Lilly — NDA Organization
- Sep 30, 1996
CheplaPharm — Marketing Organization
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
- Sep 29, 2006
Roxane Laboratories — Marketing Organization
- Sep 29, 2006
Boehringer Ingelheim — Marketing Organization
2010s
- Oct 24, 2011
Strides Pharma Science — Marketing Organization
- Oct 24, 2011
Apotex — Marketing Organization
- Oct 24, 2011
Dr. Reddy's Laboratories — Marketing Organization
- Oct 24, 2011
Par Pharmaceuticals — Marketing Organization
- Oct 24, 2011
Sandoz — Marketing Organization
- Oct 24, 2011
Teva — Marketing Organization
- Oct 24, 2011
Novartis — Marketing Organization
- Jan 30, 2012
Barr Laboratories — Marketing Organization
- Feb 28, 2012
Sun Pharmaceuticals — Marketing Organization
- Mar 20, 2012
Sankyo — Marketing Organization
- Mar 20, 2012
Lutipold — Marketing Organization
- Mar 20, 2012
Daiichi Sankyo — Marketing Organization
- Apr 23, 2012
Orbion Pharms — Marketing Organization
- Apr 23, 2012
Aurobindo Pharma — Marketing Organization
- Apr 23, 2012
Natco Pharma — Marketing Organization
- Apr 23, 2012
Mylan — Marketing Organization
- Apr 23, 2012
Orchid Pharma — Marketing Organization
- Apr 23, 2012
Torrent Pharmaceuticals Limited — Marketing Organization
- Sep 12, 2012
Jubilant Innovation Ltd. — Marketing Organization
- Nov 2, 2012
Endo Pharmaceuticals — Marketing Organization
- Nov 16, 2012
Epic Pharma Llc — Marketing Organization
- Aug 15, 2014
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Aug 15, 2014
Neogen — Marketing Organization
- Apr 29, 2015
Ivax — Marketing Organization
- Oct 20, 2015
Alkem Labs Ltd — Marketing Organization
- Jan 27, 2016
Qilu Pharmaceutical Co., Ltd. — Marketing Organization
- Mar 15, 2016
Chartwell Pharmaceuticals — Marketing Organization
- Mar 15, 2016
Invagen Pharms — Marketing Organization
- Aug 30, 2016
Ajanta Pharma Ltd — Marketing Organization
- Jun 16, 2017
Hikma — Marketing Organization
- Jul 17, 2018
Zydus Discovery DMCC — Marketing Organization
- Sep 24, 2018
Jiangsu Hansoh Pharmaceutical Co., Ltd. — Marketing Organization
- Nov 19, 2018
Sunshine Lake Pharma Co., Ltd. — Marketing Organization
2020s
- Jul 31, 2020
Indoco Remedies — Marketing Organization
- Oct 22, 2020
Eugia Pharma — Marketing Organization
- Dec 31, 2020
Zhejiang Hisun Pharmaceutical Co. Ltd. — Marketing Organization
- May 28, 2021
Alkermes — NDA Secondary Org
- Feb 24, 2023
Cadila Healthcare — Marketing Organization
- Mar 22, 2023
Aspiro — Marketing Organization
Indications
Approved for
Studied for
- Aggression · Phase 4
- Alcoholism · Phase 3
- Alzheimer Disease · Phase 4
- Amyotrophic Lateral Sclerosis · Phase 2/Phase 3
- Anorexia · Phase 3
- Anorexia Nervosa · Phase 4
- Antipsychotic Agents · Phase 4
- Anxiety · Phase 4
- Anxiety Disorders · Phase 4
- Attention Deficit and Disruptive Behavior Disorders · Phase 4
- Autism Spectrum Disorder · Phase 2
- Autistic Disorder · Phase 2/Phase 3
- Behavior · Phase 4
- Biliary Tract Neoplasms · Phase 2
- Blood Glucose · Phase 3
- Body Weight · Phase 1
- Bone Marrow Transplantation · Phase 3
- Borderline Personality Disorder · Phase 3
- Breast Neoplasms · Phase 3
- Cachexia · Phase 3
- Cannabinoids · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Central Nervous System Diseases · Phase 1
- Cervical Intraepithelial Neoplasia · Phase 3
- Child Development Disorders, Pervasive · Phase 4
- Cisplatin · Phase 3
- Cognition Disorders · Phase 4
- Colorectal Neoplasms · Phase 2
- Delirium · Phase 3
- Dementia · Phase 4
- Depression · Phase 4
- Depressive Disorder · Phase 4
- Depressive Disorder, Treatment-Resistant · Phase 3
- Dermatology · Phase 4
- Developmental Disabilities · Phase 3
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Disease · Phase 3
- Drug Administration Schedule · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drug Therapy · Phase 4
- Dyskinesia, Drug-Induced · Phase 1
- Esophageal Neoplasms · Phase 2
- Fasting · Phase 1
- Feeding and Eating Disorders · Phase 4
- Gambling · Phase 3
- Genital Neoplasms, Female · Phase 3
- Haloperidol · Phase 3
- Healthy Volunteers · Phase 4
- Hematologic Neoplasms · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 3
- HIV Infections · Phase 1
- Huntington Disease · Phase 3
- Hyperglycemia · Phase 4
- Immunoassay · Phase 1
- Immunotherapy · Phase 3
- Insulin Resistance · Phase 4
- Intellectual Disability · Phase 3
- Lung Neoplasms · Phase 4
- Lymphoma · Phase 3
- Major Depressive Disorder · Phase 4
- Mania · Phase 4
- Mental Disorders · Phase 3
- Mental Health · Phase 4
- Metabolic Syndrome · Phase 4
- Mood Disorders · Phase 4
- Movement Disorders · Phase 4
- Multiple Myeloma · Phase 3
- Nausea · Phase 3
- Neoplasms · Phase 3
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Nutrition Disorders · Phase 3
- Obsessive Behavior · Phase 4
- Obsessive-Compulsive Disorder · Phase 4
- Olanzapine · Phase 3
- Opioid-Related Disorders · Phase 3
- Out-of-Hospital Cardiac Arrest · Phase 3
- Pharmacokinetics · Phase 1
- Post-Cardiac Arrest Syndrome · Phase 3
- Postoperative Nausea and Vomiting · Phase 2/Phase 3
- Progression-Free Survival · Phase 3
- Prosthesis Failure · Phase 3
- Psychophysiologic Disorders · Phase 3
- Schizophrenia, Childhood · Phase 4
- Schizophrenia Spectrum and Other Psychotic Disorders · Phase 4
- Schizophrenia, Treatment-Resistant · Phase 2
- Sleep · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Substance-Related Disorders · Phase 4
- Tardive Dyskinesia · Phase 4
- Terminally Ill · Phase 2
- Testicular Neoplasms · Phase 3
- Tinnitus · Phase 1
- Trichotillomania · Phase 4
- Vomiting · Phase 3
- Weight Gain · Phase 4
- Weight Loss · Phase 1
Mechanism of action
- Serotonin 2c (5-HT2c) receptorANTAGONIST
HTR2C antagonist
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- D2-like dopamine receptorANTAGONIST
D2-like dopamine receptor antagonist
Combination products
lybalvi
with samidorphan
Also known as olanzapine and samidorphan
symbyax
with fluoxetine
Approval history
- approvedSep 30, 1996
Chemistry & pharmacology
SMILES
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O- Mol. weight
- 718.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3989694 ↗
- WikipediaOlanzapine ↗
- NCATSN7U69T4SZR ↗
- ChEMBLCHEMBL715 ↗
- ChEMBLCHEMBL2096647 ↗
- ChEMBLCHEMBL1201741 ↗
Also known as
- 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno(2,3-b)(1,5)benzodiazepine
- 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine
- 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine
- arkolamyl
- ly-170052
- ly 170053
- ly 170053
- ly-170053
- ly-170053
- ly-170053
- olanzapin
- olanzapin
- olanzapina
- olanzapina
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine
- olanzapine embonate
- olanzapine hydrochloride
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate
- olanzapine pamoate monohydrate
- olanzapinum
- olanzapinum
- zalasta
- zalasta
- zolafren
- zyprexa
- zyprexa
- zyprexa
- zyprexa
- zyprexa
- zyprexa
- zyprexa relprevv
- zyprexa relprevv
- zyprexa zydis
- zyprexa zydis
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06995508 | Phase 2 | Nov 15, 2025 | State University of New York, Buffalo |
| NCT07246187 | Phase 3 | Nov 6, 2025 | Mercy Bon Secours Saint Vincent Medical Center |
| NCT07208305 | Phase 3 | Sep 30, 2025 | Qinghai University |
| NCT07035821 | Phase 3 | Jul 1, 2025 | Jiao Tong University |
| NCT06850454 | Phase 3 | Jan 10, 2025 | Mahidol University |
| NCT06554613 | Phase 2 | Dec 1, 2024 | Nanchang University |
| NCT06588413 | Phase 3 | Oct 31, 2024 | Augusta University |
| NCT06251635 | N/A | Jun 3, 2024 | University of Toronto |
| NCT06500234 | Phase 3 | Jun 1, 2024 | Qingdao Central Hospital |
| NCT06331520 | Phase 3 | May 1, 2024 | Fudan University |
| NCT06200181 | Phase 3 | Apr 2, 2024 | University of Texas at Houston |
| NCT06253546 | Phase 1 | Mar 28, 2024 | Teva |
| NCT06319170 | Phase 1 | Mar 28, 2024 | Teva |
| NCT06338683 | Phase 3 | Mar 20, 2024 | Qinghai Red Cross Hospital |
| NCT06315283 | Phase 1 | Mar 20, 2024 | Teva |
| NCT05705492 | Phase 2 | Jan 31, 2024 | National Cancer Institute (NCI), OHSU Knight Cancer Institute, Oregon Health and Science University |
| NCT06517199 | Phase 3 | Jan 22, 2024 | Mahidol University |
| NCT05964647 | Phase 1 | Dec 1, 2023 | University of Basel |
| NCT06600477 | Phase 1 | Oct 16, 2023 | Neurelis, Inc. |
| NCT06107803 | Phase 1 | Oct 13, 2023 | Minerva Neurosciences |
Organizations
Research & Development (272)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 78 | 55 | 5 | 1998 |
| National Institute of Mental Health (NIMH) | Government | 28 | 5 | 5 | 1992 |
| Johnson and Johnson | For profit | 17 | 17 | 4 | 2004 |
| Merck | For profit | 17 | 17 | 3 | 2003 |
| Pfizer | For profit | 15 | 8 | 5 | 2000 |
| University of Toronto | Academic/Hospital | 13 | 10 | 5 | 2002 |
| Janssen Pharmaceutica NV | For profit | 11 | 0 | 3 | 2000 |
| Alkermes | For profit | 9 | 9 | 3 | 2013 |
| Department of Veteran Affairs | Government | 8 | 4 | 3 | 1998 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 8 | 4 | 4 | 2000 |
| Washington University in St. Louis | Academic/Hospital | 8 | 7 | 3 | 2000 |
| Columbia University | Academic/Hospital | 7 | 4 | 4 | 2001 |
| Lundbeck | For profit | 7 | 6 | 2 | 2006 |
| Otsuka | For profit | 7 | 5 | 2 | 2000 |
| Bristol-Myers Squibb | For profit | 6 | 1 | 2 | 2000 |
| National Cancer Institute (NCI) | Government | 6 | 3 | 3 | 2008 |
| Northwell Health | Academic/Hospital | 6 | 6 | 2 | 1998 |
| Peking University | Academic/Hospital | 6 | 5 | 2 | 2008 |
| Central South University | Academic/Hospital | 5 | 4 | 3 | 2005 |
| Government of Taiwan | Government | 5 | 1 | 1 | 2000 |
Marketing (55)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ajanta Pharma Ltd | For profit | MKTG | Aug 30, 2016 |
| Alkem Labs Ltd | For profit | MKTG | Oct 20, 2015 |
| Alkermes | For profit | NDA2 | May 28, 2021 |
| Apotex | For profit | MKTG | Oct 24, 2011 |
| Aspiro | For profit | MKTG | Mar 22, 2023 |
| Aurobindo Pharma | For profit | MKTG | Apr 23, 2012 |
| Barr Laboratories | For profit | MKTG | Jan 30, 2012 |
| Boehringer Ingelheim | For profit | MKTG | Sep 29, 2006 |
| Cadila Healthcare | For profit | MKTG | Feb 24, 2023 |
| Chartwell Pharmaceuticals | For profit | MKTG | Mar 15, 2016 |
| CheplaPharm | For profit | MKTG | Sep 30, 1996 |
| Daiichi Sankyo | For profit | MKTG | Mar 20, 2012 |
| Dr. Reddy's Laboratories | For profit | MKTG | Oct 24, 2011 |
| Eli Lilly | For profit | SYN | Dec 11, 2009 |
| Eli Lilly | For profit | IND | — |
| Eli Lilly | For profit | NDA | Sep 30, 1996 |
| Endo Pharmaceuticals | For profit | MKTG | Nov 2, 2012 |
| Epic Pharma Llc | For profit | MKTG | Nov 16, 2012 |
| Epic Pharma Llc | For profit | SYN | Nov 16, 2012 |
| Eugia Pharma | For profit | MKTG | Oct 22, 2020 |
| Hikma | For profit | SYN | Jun 16, 2017 |
| Hikma | For profit | MKTG | Jun 16, 2017 |
| Indoco Remedies | For profit | MKTG | Jul 31, 2020 |
| Indoco Remedies | For profit | SYN | Jul 31, 2020 |
| Invagen Pharms | For profit | MKTG | Mar 15, 2016 |
| Ivax | For profit | MKTG | Apr 29, 2015 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | MKTG | Sep 24, 2018 |
| Jubilant Innovation Ltd. | For profit | MKTG | Sep 12, 2012 |
| Lutipold | For profit | MKTG | Mar 20, 2012 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Aug 15, 2014 |
| Mylan | For profit | SYN | Apr 23, 2012 |
| Mylan | For profit | MKTG | Apr 23, 2012 |
| Natco Pharma | For profit | MKTG | Apr 23, 2012 |
| Neogen | For profit | MKTG | Aug 15, 2014 |
| Novartis | For profit | MKTG | Oct 24, 2011 |
| Orbion Pharms | For profit | MKTG | Apr 23, 2012 |
| Orchid Pharma | For profit | MKTG | Apr 23, 2012 |
| Par Pharmaceuticals | For profit | MKTG | Oct 24, 2011 |
| Qilu Pharmaceutical Co., Ltd. | For profit | SYN | Jan 27, 2016 |
| Qilu Pharmaceutical Co., Ltd. | For profit | MKTG | Jan 27, 2016 |
| Roxane Laboratories | For profit | MKTG | Sep 29, 2006 |
| Sandoz | For profit | SYN | Nov 16, 2012 |
| Sandoz | For profit | MKTG | Oct 24, 2011 |
| Sankyo | For profit | MKTG | Mar 20, 2012 |
| Strides Pharma Science | For profit | MKTG | Oct 24, 2011 |
| Sun Pharmaceuticals | For profit | MKTG | Feb 28, 2012 |
| Sunshine Lake Pharma Co., Ltd. | For profit | MKTG | Jul 3, 2018 |
| Sunshine Lake Pharma Co., Ltd. | For profit | MKTG | Nov 19, 2018 |
| Sunshine Lake Pharma Co., Ltd. | For profit | SYN | Nov 19, 2018 |
| Teva | For profit | MKTG | Oct 24, 2011 |
| Torrent Pharmaceuticals Limited | For profit | SYN | Oct 25, 2011 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Apr 23, 2012 |
| Torrent Pharmaceuticals Limited | For profit | SYN | Oct 25, 2011 |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | For profit | MKTG | Dec 31, 2020 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 17, 2018 |